Vaxcyte stock holds at EUR 55.75 in late Lang & Schwarz quote
Published on 10/30/2026 at 00:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSWhat the latest quote indicates
- The latest reading provides a neutral late-session snapshot rather than evidence of a new company disclosure.
- Recent topic coverage has included analyst target changes and developments related to Vaxcyte's clinical programs.
On October 29, 2026, the latest Lang & Schwarz quote for Vaxcyte was unchanged from its previous close at EUR 55.75. The quote was recorded at 22:59:30 Berlin time and reflects the available late-session reading for the US-listed biotechnology company.
A neutral market snapshot
The unchanged comparison does not by itself indicate a new company development or establish a cause for the share-price level. For investors, it offers a timestamped view of trading conditions without a fresh daily percentage move to interpret.
Vaxcyte's English topic page lists recent coverage involving analyst target changes and clinical-program developments. Those items are separate from the late-session quote and should not be treated as a direct explanation for it.
Vaxcyte market data
- Company: Vaxcyte
- ISIN: US92243G1085
- Ticker: PCVX
- Lang & Schwarz quote: EUR 55.75 on 29 October 2026 at 22:59:30 Berlin time
- Change: 0.00% versus the previous close of EUR 55.75
Investors can follow the real-time quote of Vaxcyte stock for subsequent price updates.
For broader market context, investors can follow the current S&P 500 market context.
Further reporting and analysis are available in more news and analyses on Vaxcyte stock.
